<DOC>
	<DOCNO>NCT01680497</DOCNO>
	<brief_summary>A prospective , open-label , multi-center , observational , post-market study evaluate JUVÉDERM VOLIFT™ correction moderate severe nasolabial fold</brief_summary>
	<brief_title>Post-Market Study JUVÉDERM VOLIFT™ With Lidocaine Correction Nasolabial Folds</brief_title>
	<detailed_description />
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female 18 year age old Have 2 fully visible , approximately symmetrical nasolabial fold severity score 2 3 5point photographic nasolabial fold severity scale ( range 04 ) nasolabial fold , judge Investigator Have reasonable expectation correction injection via deep dermis , describe protocol Agree refrain undergo antiwrinkle/volumizing treatment low twothirds face ( orbital rim ) duration study Understand willing follow aspect study protocol sign date Informed Consent prior studyrelated procedure perform Be good health opinion Investigator Has undergone cosmetic facial procedure ( e.g. , face lift surgery ) may alter appearance nasolabial fold area Cosmetic injection low twothirds face ( orbital rim ) , within 6 month prior entry study , plan undergo procedure time study . NOTE : Prior treatment HA filler and/or collagen allow , provide treatment administer 6 month prior study entry Has undergone volumizing mid/lower face within 9 month prior study entry Has ever receive semipermanent filler permanent facial implant ( e.g. , calcium hydroxylapatite , polyLlactic acid , polymethylmethacrylate , silicone , expand polytetrafluoroethylene ) anywhere low face ( orbital rim ) , plan implant product time study Have history anaphylaxis , multiple severe allergy , atopy , allergy lidocaine ( amidebased anesthetic ) , HA product , Streptococcal protein , plan undergo desensitization therapy term study Be pregnant female , lactate , plan become pregnant time study Be female childbearing potential use reliable mean contraception Have receive investigational product within 30 day prior study enrollment planning participate another investigation course study Suffer uncontrolled personality disorder ( e.g. , body dysmorphia , depression ) Have history currently suffer autoimmune disease ( e.g. , rheumatoid arthritis , Crohn 's disease ) Have history streptococcal disease ( e.g. , strep throat rheumatic fever without heart complication ) Have history skin cancer Suffer porphyria Have epilepsy , control antiepilepsy therapy Current cutaneous inflammatory and/or infectious process ( e.g. , acne , herpes ) Have history treatment interferon Be ongoing regimen anticoagulation therapy ( e.g. , warfarin ) take nonsteroidal antiinflammatory drug ( NSAIDs ) ( e.g. , aspirin , ibuprofen ) substances known increase coagulation time ( e.g. , herbal supplement garlic ginkgo biloba ) within 10 day undergo study device injection . NOTE : Study device injection may delay necessary accommodate 10day period Be concurrent regimen high dos lidocaine ( 400 mg ) may cause acute toxic reaction Be concurrent regimen local anesthetic structurally relate amidetype local anesthetic Have impair cardiac conduction , severely impaired hepatic function , severe renal dysfunction Have condition situation , Investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>